Cryoport to Report Financial Results for the Three and Nine Months Ended December 31, 2016 on March 13th, 2017

IRVINE, Calif., March 2, 2017

The Company will host a conference call at 4:30 pm ET on March 13, 2017 to review its financial results and business outlook. Participants should call 1-877-407-9716 (United States) or 1-201-493-6779 (International) and request the "Cryoport call." A live audio webcast of the call will also be available on the Investor Relations section of the Company's website at www.cryoport.com or at this link. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

An archive of the webcast will be available approximately three hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.cryoport.com for a limited time. To access the replay of the webcast, please follow this link. A dial-in replay of the call will also be available to those interested until March 20, 2017.  To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay pin number: 13656576.

Change in Fiscal Year
In September 2016, the board of directors elected to change the Company's fiscal year end from March 31 to a new fiscal year end of December 31 to align Cryoport's business calendar with that of the majority of its clients in the life sciences industry. As a result of the change, Cryoport's quarterly reporting periods will be comprised of the three calendar months ending March 31, June 30, September 30, and December 31. The Company's next periodic report filed will be filed on Form 10-KT for the transition period from April 1, 2016 to December 31, 2016. For the purpose of the MD&A in the Form 10-KT and the related earnings release, the Company will compare its transitional audited nine-month period ended December 31, 2016 to the unaudited nine months ended December 31, 2015, as a result of the change in the fiscal year.

About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

Cryoport is dedicated to